Quaternary Zn–Ag–In–Se Quantum Dots for Biomedical Optical Imaging of RGD-Modified Micelles

Exploring the synthesis of new biocompatible quantum dots (QDs) helps in overcoming the intrinsic toxicity of the existing QDs composed of highly toxic heavy metals (e.g., Cd, Hg, Pb, etc.) and is particularly interesting for the future practical application of QDs in biomedical imaging. Hence, in this report, a new one-pot approach to oil-soluble (highly toxic heavy metal-free) highly luminescent quaternary Zn–Ag–In–Se (ZAISe) QDs was designed. Their photoluminescence (PL) emission could be systematically tuned from 660 to 800 nm by controlling the Ag/Zn feed ratio, and their highest PL quantum yield is close to 50% after detailed optimization. Next, by using biodegradable RGD peptide (arginine–glycine–aspartic acid)-modified N-succinyl-N′-octyl-chitosan (RGD-SOC) micelles as a water transfer agent, the versatility of these quaternary ZAISe QDs for multiscale bioimaging of micelles (namely, in vitro and in vivo evaluating the tumor targeting of drug carriers) was further explored, as a promising alternative for Cd- and Pb-based QDs

Additional file 3 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 3. Fig. S2: The MOA of bsAbs clinical trials. (A-B) The number of MOAs of international companies and China-initiated or involved companies, respectively. (C-D) Surface plot of MOA of international companies and China-initiated or involved companies, respectively

Additional file 2 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 2. Fig. S1: Geographic distribution of anticancer bsAbs clinical trials. (A) Clinical trials of worldwide companies. (B) Clinical trials of China-initiated or involved R&D pharmaceutical companies

<i>In Vivo</i> Targeted Deep-Tissue Photodynamic Therapy Based on Near-Infrared Light Triggered Upconversion Nanoconstruct

Two major challenges of current photodynamic therapy (PDT) are the limited tissue penetration of excitation light and poor tumor-selectivity of the photosensitizer (PS). To address these issues, we developed a multifunctional nanoconstruct consisting of upconversion nanoparticles (UCNPs) that transform near-infrared (NIR) light to visible light and a photosensitizer zinc(II) phthalocyanine (ZnPc). Folate-modified amphiphilic chitosan (FASOC) was coated on the surface of UCNPs to anchor the ZnPc close to the UCNPs, thereby facilitating resonance energy transfer from UCNPs to ZnPc. Confocal microscopy and NIR small animal imaging demonstrated the enhanced tumor-selectivity of the nanoconstructs to cancer cells that overexpressed folate receptor. Reactive oxygen species (ROS) generation in cancer cells under a 1-cm tissue was higher upon excitation of UCNPs with the 980 nm light than that with 660 nm irradiation. <i>In vivo</i> PDT treatments for deep-seated tumors demonstrated that NIR light-triggered PDT based on the nanoconstructs possessed remarkable therapeutic efficacy with tumor inhibition ratio up to 50% compared with conventional visible light-activated PDT with a noticeable reduced tumor inhibition ratio of 18%. These results indicate that the multifunctional nanoconstruct is a promising PDT agent for deep-seated tumor treatment and demonstrate a new paradigm for enhancing PDT efficacy

Additional file 1 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 1. Supplementary Methods and Table S1–6

DataSheet_1_MiR-629-5p Promotes Prostate Cancer Development and Metastasis by Targeting AKAP13.zip

Prostate cancer (PCa) has become the most frequently occurring cancer among western men according to the latest report, and patients’ prognosis is often poor in the event of tumor progression, therefore, many researches are devoted to exploring the molecular mechanism of PCa metastasis. MicroRNAs (miRNA) have proved to play an important role in this process. In present study, by combining clinical samples with public databases, we found that miR-629-5p increased to varying degrees in primary localized PCa tissues and metastatic PCa tissues compared with adjacent normal tissues, and bioinformatics analysis suggested that high level of miR-629-5p was related to poor prognosis. Functionally, miR-629-5p drove PCa cell proliferation, migration and invasion in vitro, and promoted growth of PCa cells in vivo. Moreover, A-kinase Anchor Protein 13 (AKAP13) was screened as a direct target of miR-629-5p, that expression was negatively correlated with the malignant phenotype of tumor cells. In the end, through verification in clinical specimens, we found that AKAP13 could be independently used as a clinical prognostic indicator. Overall, the present study indicates that miR-629-5p plays an oncogenic role in PCa by targeting AKAP13, which provides a new idea for clinical diagnosis and treatment of complex refractory PCa.</p

Additional file 1 of EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Additional file 1: Table S1. Gene lists of targeted next-generation sequencing panels our study involved

MOESM1 of A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

Additional file 1. Questionnaire for survey of the clinical features and management of bone metastatic disease in China

Additional file 6 of Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer

Additional file 6. Study protocol and amendment records

Additional file 3 of Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Table S1. Quality assessment: risk of bias by Cochrane Collaboration’s tool. Table S2. Additional characteristics of patients comparing IO-Chemotherapy with Chemotherapy in Included trials. Table S3. Main outcomes of the included trials. Table S4. Summary of the data status for subgroup-analyses among the included trials. Table S5. Summary of sensitivity analyses results using both fixed-effects and random-effects models. Table S6. Summary of sensitivity analyses after removing studies that were only available from conference presentation. (PDF 982 kb